According to Deutsche Bank, Gilead Sciences GILD 2Q looks to miss.
Deutsche Bank said that IMS script trends, after begin adjusted for pricing, suggests QoQ growth is not sufficient to meet US HIV Gilead rev consensus of $950M. “Our est adjusts for patients in 1Q11 given free drug in florida temporarily (we estimate $3.6M was lost on Wellvista patients in 1Q11).”
Gilead Sciences closed on Friday at $42.44.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
